PriceSensitive

AnteoTech (ASX:ADO) appoints David Radford as new CEO

ASX News, Technology
ASX:ADO      MCAP $50.57M
19 July 2022 13:19 (AEST)

This browser does not support the video element.

Life science and energy tech company AnteoTech (ADO) has appointed David Radford as its new Managing Director and CEO.

The appointment follows a five-month search after CEO Derek Thomson announced his resignation in mid-March.

Mr Radford is an internationally experienced CEO and Company Director and has experience in coordinating international teams, executing business turnarounds,
product development and product launches, and operational initiatives to drive material growth in revenue and profits.

Recently, he was the CEO of Australian medical device company AllVascular, which
develops and sells patented drug delivery technology.

Mr Radford will begin his new roles on October 4 when Mr Thomson finishes his six-month notice period in accordance with his contract.

“I thank the AnteoTech board for the opportunity to join the company as CEO, at what marks a particularly exciting time in the company’s evolution,” Mr Radford said.

“Through my engagement with the board, I am confident the business has established a strong foundation to deliver on its core operational objectives in the months and years ahead.”

Chairman Ewen Crouch has thanked Mr Thomson for his contribution to the company and is looking forward to working with Mr Radford.

“The board considered that Mr Radford’s strategic acumen, industry knowledge and high-level C-suite experience made him the standout candidate from a competitive field of applicants following an extensive global search process,” he said.

ADO shares were up 4.11 per cent on the market and trading at 7.6 cents at 1:13 pm AEST.

Related News